Vimarsana
Biggest News Aggregation in the World

Page 5 - Pooled Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pooled Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pooled Analysis Today - Breaking & Trending Today

Severe Alopecia Areata Patients Without Regrowth of Scalp Hair Benefit from Dose Increase of Baricitinib - Vimarsana News

Severe Alopecia Areata Patients Without Regrowth of Scalp Hair Benefit from Dose Increase of Baricitinib

Published: August 11, 2023

This new data may need to be examined by health providers when they advise patients about treatment outcomes for increasing dosage, including those who could benefit from a higher dose of baricitinib.

Source: hcplive.com
Related Topics:
United StatesJustinm KoAmerican Academy Of Dermatology Annual MeetingAlopecia ToolStanford UniversityBaricitinib TherapyPatients With Severe Alopecia AreataPooled AnalysisDermatology Annual MeetingNew Orleans
Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting - Vimarsana News

Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting

Published: June 8, 2023

A Total of 11 Poster Presentations Will Be Presented, Including Data from Two Pivotal Phase 3 Trials and 12-Month Safety Extension Trial of MIEBO™ ... | June 8, 2023

Source: marketscreener.com
Related Topics:
New JerseyUnited StatesNora CothranJames DeomJessica SteenPaul KarpeckiMelissa BarnettJustin SchweitzerBen GaddieDerek CunninghamResearch DevelopmentAmerican Optometric AssociationDrug Administration OnLomb CorporationExchange CommissionWaltere Washington Convention CenterVirtual EventDrug AdministrationHydration Boost Contact Lens Rehydrating DropsYehia HashadBiotrue Hydration BoostNew Preservative Free LubricatingAntioxidant Erythritol Protects HyaluronanFree RadicalsLumify Eye Illuminations
Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology® - Vimarsana News

Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®

Published: June 5, 2023

/PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium...

Source: prnewswire.com
Related Topics:
Matthewj ZiegelmannMatthew ZiegelmannGenzhou LiuLandon TrostQinfang XiangMichaelp MclaneExchange CommissionEndo InternationalPrnewswire Endo InternationalTreatment ResponseCycle With Collagenase Clostridium HistolyticumPooled AnalysisTwo PhaseRisk EvaluationMitigation StrategyIncluding AnaphylaxisAbnormal CoagulationPost Injection Back Pain ReactionsPrescribing InformationBoxed WarningPrivate Securities Litigation Reform ActBankruptcy CodeAnnual ReportQuarterly ReportsEndo International Plc
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial - Vimarsana News

TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial

Published: June 4, 2023

Treatment with adjuvant TAGRISSO reduced the risk of death by more than half ... | June 4, 2023

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomLe ChevalierDaiichi SankyoAmerican Society Of Clinical OncologyCollaborative GroupInternational Agency For Research On CancerData Monitoring CommitteeLungevity FoundationArchives Pathology LabWorld Health OrganisationLung Ambition AlliancePlenary SessionClinical OncologyAnnual MeetingPrescribing InformationPatient InformationSouth AmericaIndependent Data Monitoring CommitteeRare DiseasesInternational AgencyLung FactAccessed MarchCancer BiomarkersPresent Status
AstraZeneca: TAGRISSO achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial - Vimarsana News

AstraZeneca: TAGRISSO achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial

Published: June 4, 2023

Treatment with adjuvant TAGRISSO reduced the risk of death by more than half Positive results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) demonstrated a statistically

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomChelsea FordLe ChevalierDaiichi SankyoBrendan McevoyLung Ambition AllianceWorld Health OrganisationArchives Pathology LabLungevity FoundationData Monitoring CommitteeInternational Agency For Research On CancerAmerican Society Of Clinical OncologyCollaborative GroupPlenary SessionClinical OncologyAnnual MeetingPrescribing InformationPatient InformationSouth AmericaIndependent Data Monitoring CommitteeRare DiseasesRenal MetabolismInternational AgencyLung Fact